Bibliographic Details
| Title: |
Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. |
| Authors: |
Chieh-Lung Cheng1, Chi-Cheng Li2, Hsin-An Hou1, Wei-Quan Fang3, Chin-Hao Chang4, Chien-Ting Lin2, Jih-Luh Tang1, Wen-Chien Chou1,5, Chien-Yuan Chen1, Ming Yao1, Shang-Yi Huang1, Bor-Sheng Ko1, Shang-Ju Wu1, Woei Tsay1, Hwei-Fang Tien1 hftien@ntu.edu.tw |
| Source: |
BMC Cancer. 2015, Vol. 15 Issue 1, p1-10. 10p. |
| Subject Terms: |
*MYELOID leukemia, *CENTRAL nervous system diseases, *CYTOGENETICS, *GENETIC mutation, *MOLECULAR genetics, DISEASES in adults |
| Abstract: |
Background: Acute myeloid leukaemia (AML) with central nervous system (CNS) involvement in adults is uncommon, and studies of this subject are scant. Methods: We conducted a retrospective study to investigate the clinical aspects, cytogenetic abnormalities, molecular gene mutations and outcomes of adult AML patients with CNS involvement. Three hundred and ninety-five patients with newly diagnosed AML were reviewed. Results: Twenty (5.1%) patients had CNS involvement, including 7 (1.8%) with initial CNS disease and 4 (1%) who suffered an isolated CNS relapse. The patients with CNS involvement were younger, had higher leukocyte, platelet, and peripheral blast cell counts, FAB M4 morphology, and chromosome translocations involving 11q23 (11q23 abnormalities) more frequently than did the patients without CNS involvement. No differences in sex, haemoglobin levels, serum LDH levels, immunophenotype of leukaemia cells, or molecular gene mutations were observed between the two groups. Multivariate analyses showed that age ≤ 45 years (OR, 5.933; 95% CI, 1.82 to 19.343), leukocyte counts ≥ 50,000/μl (OR, 3.136; 95% CI, 1.083 to 9.078), and the presence of 11q23 abnormalities (OR, 5.548; 95% CI, 1.208 to 25.489) were significant predictors of CNS involvement. Patients with initial CNS disease had 5-year overall survival and relapse-free survival rates that were similar to those without initial CNS disease. However, three of four patients who suffered an isolated CNS relapse died, and their prognosis was as poor as that of patients who suffered a bone marrow relapse. Conclusion: CNS involvement in adult patients with AML is rare. Three significant risk factors for CNS involvement including age ≤ 45 years, leukocyte counts ≥ 50,000/μl and the presence of 11q23 abnormalities were identified in this study. Future investigations to determine whether adult AML patients having these specific risk factors would benefit from CNS prophylactic therapy are necessary. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Cancer is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
